Understanding how some advanced cancer patients benefit long-term from immune therapies
Official title: A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors
Funded at Roswell Park Cancer Institute Corp · NIH-10929397 · Data updated 2026-11-12
This study is looking at patients with advanced cancer who have had lasting positive results from certain immune treatments, to learn more about what helps them live longer and how to support their needs better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | September 14, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $735,428 |
| NIH project number | 5R01CA281862-02 |
| Project ID | NIH-10929397 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced lung cancer, kidney cancer, or melanoma who have shown a durable response to immune checkpoint inhibitors.
✕Less likely to help
Patients who have not received immune checkpoint inhibitors or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates patients with advanced cancer who have experienced long-lasting benefits from immune checkpoint inhibitors (ICIs). It involves two groups: a large retrospective analysis of over 8,800 patients treated with ICIs from 2014 to 2022, and a prospective cohort of about 1,200 patients with durable responses to ICIs, specifically focusing on lung, kidney, and melanoma cancers. The study aims to collect clinical data and patient-reported outcomes to better understand the factors contributing to long-term survival and the ongoing needs of these patients. By following these patients over time, the research seeks to illuminate their symptom trajectories and survivorship challenges.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding of how to enhance treatment outcomes for patients with advanced cancer receiving immune therapies.
How similar studies have gone: Previous research has shown promising results in understanding patient responses to immune therapies, making this study a continuation of that successful exploration.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Yao, Song — Roswell Park Cancer Institute Corp
- Study coordinator: Yao, Song
Related research
Other NIH-funded projects on the same topics.
-
Survivors living with advanced cancer after durable response to immune therapy
This grant follows people who had advanced cancer and responded well to immune checkpoint inhibitors to understand what helps them stay well and how their symptoms change over time.
-
Survivorship after lasting benefit from immunotherapy for advanced cancer
This project follows people with advanced cancers who have had long-lasting benefit from immunotherapy to track their health, symptoms, and care needs over time.
-
Understanding how survivorship care plans affect health outcomes for cancer survivors
A study will look at whether survivorship care plans help reduce deaths and improve health for adults who have survived cancer.
-
Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients
This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.
-
Meaning-Centered Psychotherapy for Mexican Patients with Advanced Cancer
A cancer center in Mexico will test a culturally adapted therapy to help Mexican patients with advanced cancer find meaning, peace, and purpose at the end of life.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.